ARCHIVES

CMS Considering Regulatory Standards for Drug Company Bundling of Products.

This article is from The Cancer Letter archive.

Vol. 32 No. 37 | October 20, 2006

Download PDF Visit The Full Archive

Related Articles

DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing

July 10, 1992

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

Phase III PANORAMA-1 Trial Meets PFS Primary Endpoint

June 27, 2014

McKay Retires As Fox Chase Executive, Is Succeeded By Donald Leedy As VP.

June 2, 2000

NCI Sets Initial R01 Payline At 18th Percentile Under CR.

November 24, 2000

Patient Advocacy: Breast Cancer Coalition Forms PAC To Increase Political Activities

April 18, 1997